Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus TECHNETIUM TC99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus TECHNETIUM TC99M MERTIATIDE KIT.
MPI DMSA KIDNEY REAGENT vs TECHNETIUM TC99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical